For nearly 25 years, the federal drug discount program has been in effect and a part of the healthcare provider support model. For many safety net providers, the 340B program is integrated into their business process and service delivery models with program savings a key driver in the ability to continue providing comprehensive services to all patients.
The 340B program was a hot topic in Washington, D.C., in 2017, with the introduction of an enhanced HRSA audit process, multiple congressional hearings, CMS changes that will affect many entities' reimbursement, and discussions about other areas that may see future changes. We will recap 2017, including the OPPS Final Rule that will force some hospitals and service providers to deal with a significant drop in Medicare Part B reimbursement and use new claims-level modifiers to identify drugs purchased through the 340B program. We will also discuss other areas that may be susceptible to future changes and provide information on how to stay abreast of program updates in 2018 and beyond. We’ll finish up the presentation by detailing monitoring procedures that may assist entities in validating compliance with program requirements and preparing them for HRSA/The Bizzell Group audits.
As a result of viewing this on-demand webinar, you should be able to: